Open Access<p>Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study</p>
Author(s) -
Ning An,
Haoyi Wang,
Ji Li,
Xuechao Zhai,
Jing Wang,
Wang Jia,
Li Kong,
Hui Zhu,
Jinming Yu
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s223216
Subject(s) - medicine , oncology , brain metastasis , radiation therapy , retrospective cohort study , incidence (geometry) , lung cancer , progression free survival , cancer , metastasis , chemotherapy , physics , optics
Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering from a high incidence of brain metastasis (BM). It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. This study aims to investigate the therapeutic effect of TKIs combined with concurrent cranial radiotherapy on BM.